Clarify the Norofis virus molecules
J Marshall/Tribaleye Images/Alamy
Norofis virus pollen can be available that reduces the risk of infection within a few years, after it showed a promise in a trial where people intentionally exposed to the virus.
It affects the highly gastric virus the stomach and intestine, causing vomiting and diarrhea, which usually solves within a few days. Billions of economics worldwide say every year because of the missing days of work and hospitalization. ” Sarah Kadi At Cornell University in Ethaka, New York.
Sean Taker At Biotech Company Vaxart in San Francisco and his colleagues, they previously developed an oral vaccine IGA reinforced levels that can prevent the Norofis virus From entering cells, which indicates that it can prevent infections.
Now, this researchers tested 141 people between the ages of 18 and 49, about half of them took birth control pills, while others took a fake medicine. A month later, all the participants deliberately swallowed a high dose of the Gi.1 breed of the Norofille virus in a liquid form, while in the quarantine. “In the real world position, you need to hit 10 to 100 viral islands, and we use a million particles,” says Taker. This helped ensure that a sufficient number of people are injured, he says.
The following week, 82 percent of the fictitious drug group was wounded, but only 57 percent of the participants who were vaccinated.
“I think most individuals will be interested in taking it [the vaccine] If you can reduce your risk about it [25 percentage points] “And it avoids getting symptoms of insults,” says Kadi, who did not participate in the study.
The team also found that the participants who were vaccinated are a much lower virus in stool and vomiting than those who took the placebo. This indicates that the vaccine can slow down the virus, although it must be tested directly, says Caddy.
In another analysis, scientists emphasized that the vaccine may work by enhancing the levels of IGA antibodies in saliva, intestine, blood and nose.
However, it is unclear how long this protection will continue. More work is also needed to verify the results of young children and the elderly who are particularly risk of transporting the hospital.
Most of the human viruses that affect humans belong to two groups, known as Gi and Gii. Based on an unpublished action by his team, he will likely protect the Gi.1 vaccine from other variables closely related, says Taker. The team also develops a vaccine that can protect against GI and Gii viruses.
If things go well, Tucker hopes that the Gi.1 vaccine will be released within two to three years.
Topics:
